Levine Aidan A, Levine Todd D, Clarke Kathie, Saperstein David
Phoenix Neurological Associates, 5090 North 40th Street, Suite 250, Phoenix, Arizona, USA.
Muscle Nerve. 2017 Dec;56(6):1173-1176. doi: 10.1002/mus.25693. Epub 2017 May 30.
For patients receiving intravenous immunoglobulin (IVIg), renal and hemolytic side effects are well recognized. However, there are very few data on the effects of chronic IVIg therapy.
We retrospectively analyzed laboratory data on 166 patients who received IVIg for 12 months with a dose range of 0.441-2.58 g/kg/month, measuring changes in hematocrit and glomerular filtration (GFR) rates at 6 and 12 months.
Of the 2,232 infusions, there were no incidents of clinical hemolysis. However, after 12 months of treatment, 21% of patients had a ≥3-g/dl decline in hematocrit and 10% had a ≥20% decline in GFR.
No clinically significant hemolysis was observed in patients receiving chronic IVIg therapy. However, a significant number of patients had a decline in hematocrit and/or GFR while on therapy. This emphasizes the need for observation of hematologic and renal function in patients treated with chronic IVIg. Muscle Nerve 56: 1173-1176, 2017.
对于接受静脉注射免疫球蛋白（IVIg）治疗的患者，肾脏和溶血副作用已广为人知。然而，关于慢性IVIg治疗效果的数据却非常少。
我们回顾性分析了166例接受IVIg治疗12个月的患者的实验室数据，剂量范围为0.441 - 2.58克/千克/月，在6个月和12个月时测量血细胞比容和肾小球滤过率（GFR）的变化。
在2232次输注中，未发生临床溶血事件。然而，治疗12个月后，21%的患者血细胞比容下降≥3克/分升，10%的患者GFR下降≥20%。
在接受慢性IVIg治疗的患者中未观察到具有临床意义的溶血现象。然而，大量患者在治疗期间血细胞比容和/或GFR下降。这强调了对接受慢性IVIg治疗的患者进行血液学和肾功能观察的必要性。《肌肉与神经》56: 1173 - 1176, 2017年。
